in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
193<br />
PDGF-stimulated Balb/c 3T3 proliferation<br />
cellul ar<br />
Ref. 0253<br />
[CUSTOM OFFER]<br />
Source<br />
Stimulant<br />
Tracer<br />
Measured product<br />
Detection method<br />
Balb/c 3T3 cells<br />
PDGF-BB (3 ng/mL)<br />
[ 3 H]TMD (1 µCi)<br />
[ 3 H]TMD <strong>in</strong>corporation<br />
sc<strong>in</strong>tillation count<strong>in</strong>g<br />
Reference<br />
cycloheximide (IC 50 : 100 nM)<br />
Handler, J.A. et al. (1990) J. Biol. Chem., 265: 3669-3673.<br />
[ 3 H]TMD <strong>in</strong>corporation (dpm)<br />
cell proliferation ❚<br />
100<br />
50<br />
0<br />
cycloheximide<br />
-10 -9 -8 -7 -6 -5 -4<br />
log [drug] (M)<br />
<strong>Cerep</strong><br />
services<br />
Receptors<br />
VEGF-stimulated HUV-EC-C proliferation<br />
cellul ar<br />
Ref. 0937<br />
[CUSTOM OFFER]<br />
Source<br />
HUV-EC-C cells<br />
Stimulant<br />
VEGF (10 nM)<br />
Tracer<br />
[ 3 H]TMD (0.2 µCi)<br />
Measured product [ 3 H]TMD <strong>in</strong>corporation<br />
Detection method sc<strong>in</strong>tillation count<strong>in</strong>g<br />
Reference<br />
TNFα (IC 50 : 4.4 pM)<br />
[Solvent] must be kept ≤ 0.1%<br />
Mauerhoff, T. et al. (1994) Tumori, 80: 301-305.<br />
[ 3 H]TMD <strong>in</strong>corporation (dpm)<br />
100<br />
50<br />
0<br />
-50<br />
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4<br />
log [drug] (M)<br />
TNFα<br />
staurospor<strong>in</strong>e<br />
Ion<br />
channels<br />
Transporters<br />
PHA-stimulated PBMC proliferation<br />
cellul ar<br />
Ref. 0254<br />
[CUSTOM OFFER]<br />
Source<br />
PBMC<br />
Stimulant PHA (2 µg/mL)<br />
Tracer<br />
[ 3 H]TMD (1 µCi)<br />
Measured product [ 3 H]TMD <strong>in</strong>corporation<br />
Detection method sc<strong>in</strong>tillation count<strong>in</strong>g<br />
Reference<br />
staurospor<strong>in</strong>e (IC 50 : 19 nM)<br />
[Solvent] must be kept ≤ 0.1%<br />
Gougerot-Pocidalo, M.A. et al. (1988) Immunology, 64: 281-288.<br />
[ 3 H]TMD <strong>in</strong>corporation (% of control)<br />
100<br />
50<br />
0<br />
staurospor<strong>in</strong>e<br />
-10 -9 -8 -7 -6<br />
log [drug] (M)<br />
K<strong>in</strong>ases<br />
Epigenetic &<br />
DNA-related<br />
enzymes<br />
❚ Cell viability<br />
Other<br />
enzymes<br />
cell viability<br />
Source<br />
U-937, HUVEC, PBMC, THP-1, A7r5,<br />
HL-60 or SK-N-SH cells<br />
Substrate<br />
MTT (0.5 mg/mL)<br />
Measured product formazan<br />
Detection method photometry<br />
cellul ar<br />
0<br />
Reference<br />
erythromyc<strong>in</strong> or PMA<br />
erythromyc<strong>in</strong><br />
0.1 0.3 1.0<br />
Ref. 0274<br />
n To be comb<strong>in</strong>ed with secretion assays<br />
[erythromyc<strong>in</strong>] (mg/mL)-24h <strong>in</strong>cubation<br />
[CUSTOM OFFER]<br />
Mosmann, T. (1983) J. Immunol. Met., 65: 55-63.<br />
❚ Cellular models such as human primary hepatocytes, and other technology such alamarBlue are available: see ADME-Tox & PK <strong>2011</strong> catalog<br />
PBMC viability (% of viable cells)<br />
100<br />
50<br />
<br />
Specialized<br />
cellular<br />
assays<br />
Standard<br />
profiles<br />
Test<strong>in</strong>g<br />
conditions<br />
Order<strong>in</strong>g<br />
<strong>in</strong>formation<br />
For further details and updated <strong>in</strong>formation on assays:<br />
❚ Please go to www.cerep.com catalog onl<strong>in</strong>e or contact us at sales@cerep.com<br />
❚ Europe: +33 (0)5 49 89 30 00 – USA: +1 (425) 895 8666 – Japan: +81 (0)3 3354 4026 – Ch<strong>in</strong>a: +86 21 5132 0568<br />
Human Q Standard turnaround time [CUSTOM OFFER] Please contact us at: customresearch@cerep.com<br />
Assay list<br />
& <strong>in</strong>dex
Change language